CPR2 Antibody

What is CPR2 antibody and what are its primary applications?

CPR2 antibody is a polyclonal antibody that recognizes the CPR2 protein, which in human research contexts is often identified as an alternative name for TBRG4 (Transforming Growth Factor Beta Regulator 4) . This protein contains putative leucine zipper domains characteristic of transcription factors and may play a role in cell cycle progression according to research findings (PMID:9383053) . The antibody has been validated for multiple laboratory applications including ELISA, Western blot (WB), immunofluorescence (IF), and immunoprecipitation (IP) . When using this antibody, researchers should account for the observed molecular weight range of 60-71 kDa in Western blot applications, as indicated by validation studies . In some research contexts, CPR2 antibody may also refer to an antibody that recognizes a yeast/fungi antigen, demonstrating its diverse research applications across different biological systems .

What are the recommended storage conditions and handling procedures for CPR2 antibody?

For optimal antibody performance, CPR2/TBRG4 antibody should be stored at -20°C in its original formulation of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . According to manufacturer recommendations, researchers should avoid repeated freeze-thaw cycles that can degrade antibody quality and compromise experimental results . The documentation specifically emphasizes that researchers should NOT ALIQUOT the antibody, suggesting that the stability of this particular formulation may be negatively affected by dividing the stock solution . When working with the antibody, proper laboratory safety procedures should be followed, particularly due to the presence of sodium azide in the formulation, which is a toxic compound that can also form explosive compounds with heavy metals in plumbing systems over time.

What are the recommended dilutions for different applications of CPR2 antibody?

Based on validation studies, the recommended working dilutions for CPR2/TBRG4 antibody vary depending on the specific application . For Western blot applications, the manufacturer recommends a dilution range of 1:500 to 1:5000, allowing researchers to optimize based on their specific sample and detection system . For immunoprecipitation procedures, a dilution range of 1:200 to 1:2000 is suggested for optimal results . For immunofluorescence applications, the manufacturer indicates that specific dilution recommendations are not available (N/A), suggesting that researchers would need to conduct preliminary optimization experiments to determine the appropriate concentration for this application . These dilution ranges serve as starting points, and researchers should conduct their own optimization experiments based on their specific experimental conditions, sample types, and detection methods.

How can researchers validate the specificity of CPR2/TBRG4 antibody in their experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For CPR2/TBRG4 antibody, researchers can employ multiple complementary approaches. First, perform Western blot analysis using positive control lysates from cells known to express the target protein, such as HepG2 cells, HeLa cells, human liver tissue, or mouse ovary tissue, which have been documented to show positive results with this antibody . Second, incorporate negative controls by using samples from tissues known to have little to no expression of the target, as RT-PCR ELISA has detected moderate expression of TBRG4 in ovary but little to no expression in other tissues examined (PMID:10231032) . Third, consider using genetic approaches such as siRNA or CRISPR-Cas9 to knock down or knock out the target gene and confirm the corresponding reduction or loss of signal in your detection system. Finally, for definitive validation, researchers might consider immunoprecipitation followed by mass spectrometry to confirm that the antibody is indeed capturing the intended target protein.

What is known about the expression pattern of CPR2/TBRG4 and how might this inform experimental design?

The expression pattern of CPR2/TBRG4 has important implications for experimental design in antibody-based studies. According to RT-PCR ELISA data, moderate expression of TBRG4 has been detected in ovary tissue, with little to no expression observed in other tissues and specific brain regions examined (PMID:10231032) . This restrictive expression profile suggests that researchers should carefully select positive control tissues (e.g., ovary) and cell lines (validated examples include HepG2 and HeLa cells) . The limited expression also indicates that detection methods may need to be optimized for sensitivity when examining tissues with lower expression levels. Furthermore, studies investigating the functional role of CPR2/TBRG4 should consider its potential tissue-specific functions, particularly in reproductive biology given its expression in ovarian tissue. Researchers should also be aware that expression patterns may vary under different physiological or pathological conditions, necessitating careful experimental design when studying disease models or stress responses.

How does CPR2/TBRG4 relate to cellular functions in cancer research contexts?

While direct evidence for CPR2/TBRG4 in cancer is limited in the provided search results, the protein's putative role in cell cycle progression (PMID:9383053) suggests potential relevance to cancer biology research . Researchers investigating CPR2/TBRG4 in cancer contexts should consider several approaches. First, examine the protein's expression patterns across cancer cell lines and tumor samples compared to normal tissues, particularly focusing on ovarian cancers given the protein's expression in ovarian tissue . Second, explore potential interactions between CPR2/TBRG4 and known oncogenic or tumor suppressor pathways, especially those involved in cell cycle regulation. Third, consider investigating whether the leucine zipper domains characteristic of this protein mediate interactions with other transcription factors relevant to cancer progression. Finally, researchers might employ functional studies using CPR2/TBRG4 antibody for immunoprecipitation to identify interaction partners that could provide insight into its role in cancer-related cellular processes.

What are the considerations for using CPR2 antibody in combination with other antibodies for co-localization studies?

When designing co-localization experiments using CPR2/TBRG4 antibody alongside other antibodies, researchers should address several technical considerations. First, since the available CPR2/TBRG4 antibody is a rabbit polyclonal (according to search result 5), researchers must select companion antibodies from different host species (such as mouse, rat, or goat) to avoid cross-reactivity during secondary antibody detection . Second, spectral considerations are crucial - researchers should select fluorophores with minimal spectral overlap for secondary antibodies or directly conjugated primary antibodies. Third, proper controls should be implemented, including single-antibody staining controls to confirm signal specificity and rule out bleed-through between channels. Fourth, researchers should optimize the fixation and permeabilization protocols, as these can differentially affect epitope accessibility for different antibodies. Finally, when interpreting co-localization data, quantitative methods should be employed (such as Pearson's correlation coefficient or Manders' overlap coefficient) rather than relying solely on visual assessment of merged images.

What are the best practices for Western blot analysis using CPR2/TBRG4 antibody?

For optimal Western blot results with CPR2/TBRG4 antibody, researchers should implement several methodological refinements. First, sample preparation is crucial - use validated positive control samples such as HepG2 cells, HeLa cells, human liver tissue, or mouse ovary tissue, which have shown positive results in previous studies . Second, be aware of the expected molecular weight range of 60-71 kDa for the target protein, as both these bands have been observed in validated Western blots . Third, optimize antibody dilution within the recommended range of 1:500-1:5000, starting with a middle dilution (e.g., 1:2000) and adjusting based on signal strength and background levels . Fourth, incorporate proper blocking steps (typically 5% non-fat dry milk or BSA) to minimize non-specific binding and background signal. Fifth, include appropriate positive and negative controls in each experiment to validate specificity. Finally, when troubleshooting, consider adjusting transfer conditions for high molecular weight proteins, varying exposure times, and testing different detection systems (chemiluminescence vs. fluorescence) to optimize signal-to-noise ratio.

How can researchers optimize immunoprecipitation protocols using CPR2/TBRG4 antibody?

Successful immunoprecipitation (IP) using CPR2/TBRG4 antibody requires careful protocol optimization. First, determine the appropriate antibody amount, starting with the manufacturer's recommended dilution range of 1:200-1:2000, which typically translates to 2-10 μg of antibody per IP reaction . Second, optimize lysis buffer composition to effectively solubilize the target protein while preserving antibody-epitope interactions; for CPR2/TBRG4, a validated example includes successful IP detection in HepG2 cell lysates . Third, consider pre-clearing the lysate with protein A/G beads to reduce non-specific binding. Fourth, optimize incubation times and temperatures for both the antibody-lysate binding step (typically 1-4 hours at 4°C or overnight) and the bead capture step. Fifth, implement stringent washing steps to reduce background while preserving specific interactions. Finally, include appropriate controls such as an isotype-matched irrelevant antibody IP and an input sample (typically 5-10% of the starting material) to accurately assess IP efficiency and specificity in each experiment.

What are the critical factors for successful immunofluorescence using CPR2/TBRG4 antibody?

While specific immunofluorescence (IF) dilutions aren't provided for CPR2/TBRG4 antibody, successful IF has been reported in U2OS cells, COS7 cells, and HeLa cells . For optimal results, researchers should address several methodological aspects. First, fixation method significantly impacts epitope accessibility - compare paraformaldehyde (preserves morphology) with methanol/acetone (enhances accessibility for some epitopes) to determine optimal conditions for CPR2/TBRG4 detection. Second, permeabilization requires optimization; try different detergents (Triton X-100, saponin, or digitonin) at various concentrations to balance cellular access with structural preservation. Third, blocking conditions should be rigorously tested; typical options include 5-10% normal serum from the secondary antibody host species or commercial blocking buffers. Fourth, antibody concentration requires titration; begin testing at 1:100-1:500 dilutions and adjust based on signal-to-noise ratio. Fifth, signal amplification methods (such as tyramide signal amplification) might be necessary if expression levels are low, as suggested by the limited tissue expression profile of TBRG4 . Finally, include appropriate controls, including a no-primary antibody control and ideally a knockdown validation to confirm signal specificity.

How should researchers interpret variability in CPR2/TBRG4 antibody results across different experimental systems?

When confronted with variable results using CPR2/TBRG4 antibody across different experimental systems, researchers should consider several potential sources of variation. First, expression level differences are likely significant given the restricted expression pattern of TBRG4 (primarily in ovary tissue with limited expression elsewhere) . Second, post-translational modifications might affect epitope accessibility; the observed molecular weight range (60-71 kDa) suggests possible modifications that could vary across cell types or experimental conditions . Third, splice variants could contribute to variability; verify which isoforms your experimental system expresses and which epitopes the antibody recognizes. Fourth, sample preparation methods (lysis buffers, fixation protocols) might differentially affect epitope preservation across systems. Fifth, detection system sensitivity varies considerably; chemiluminescence, fluorescence, and colorimetric methods have different detection thresholds that might explain apparent discrepancies. Finally, antibody lot-to-lot variation can be substantial for polyclonal antibodies; maintain detailed records of antibody lots used and consider validating new lots against previous ones when obtained.

How does the function of CPR2 in human/mammalian systems compare to its role in fungal biology?

The search results indicate an interesting complexity regarding CPR2 across different biological kingdoms. In mammalian systems, CPR2 appears as an alternative name for TBRG4, a protein containing putative leucine zipper domains characteristic of transcription factors that may play a role in cell cycle progression . Conversely, in fungal systems, CPR2 refers to a distinct protein that serves as an antigen recognized by specific antibodies developed for yeast/fungi research applications . This nomenclature overlap presents an interesting comparative biology question. Researchers investigating potential functional parallels might consider examining whether fungal CPR2 shares any structural domains with mammalian TBRG4/CPR2, particularly the leucine zipper motifs. Additionally, comparing the subcellular localization patterns between systems could provide insights into potential conserved functions. While direct evolutionary relationships between these similarly named proteins aren't established in the search results, this represents an intriguing area for computational biology research through phylogenetic analysis and structural prediction approaches.

What is known about the role of CPR2/TBRG4 in cell cycle regulation and how can researchers investigate this function?

The putative role of CPR2/TBRG4 in cell cycle progression (PMID:9383053) presents an important area for functional investigation . Researchers interested in this aspect should consider several experimental approaches. First, cell synchronization studies combined with CPR2/TBRG4 immunoblotting or immunofluorescence could reveal cell cycle-dependent expression or localization patterns. Second, loss-of-function studies using siRNA, shRNA, or CRISPR-Cas9 targeting CPR2/TBRG4 followed by cell cycle analysis (flow cytometry with propidium iodide or BrdU labeling) would help determine if and how the protein affects cell cycle progression. Third, gain-of-function studies through overexpression systems could reveal potential dominant effects on cell cycle regulation. Fourth, co-immunoprecipitation using CPR2/TBRG4 antibody followed by mass spectrometry could identify interaction partners involved in cell cycle control. Fifth, chromatin immunoprecipitation (ChIP) assays might be valuable given the protein's putative transcription factor characteristics, potentially revealing cell cycle-related target genes. Finally, researchers should examine whether CPR2/TBRG4 undergoes post-translational modifications during different cell cycle phases, which could provide mechanistic insights into its regulatory functions.

How might the leucine zipper domains of CPR2/TBRG4 influence its molecular interactions and function?

The presence of multiple putative leucine zipper domains in CPR2/TBRG4 (PMID:9383053) suggests important functional implications that researchers can investigate through several approaches . First, structural analysis using protein modeling tools can predict how these leucine zipper domains fold and potentially interact with other proteins, particularly other transcription factors containing complementary leucine zipper domains. Second, site-directed mutagenesis of key leucine residues within these domains followed by functional assays would help determine which specific domains are critical for the protein's activities. Third, protein-protein interaction studies using techniques like yeast two-hybrid screening, proximity labeling (BioID or APEX), or co-immunoprecipitation with CPR2/TBRG4 antibody can identify binding partners that interact through these domains. Fourth, electrophoretic mobility shift assays (EMSA) could determine whether CPR2/TBRG4 directly binds DNA, as would be expected for a transcription factor with leucine zipper domains. Fifth, fluorescence resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) could visualize these interactions in living cells. Finally, researchers should investigate whether the leucine zipper domains mediate homodimerization or heterodimerization, which could have significant implications for the protein's regulatory functions.

What are the potential connections between CPR2/TBRG4 and other actin-bundling factors in cellular processes?

While the search results don't directly link CPR2/TBRG4 to actin bundling, search result discusses CRP2 (not CPR2) as an actin bundling factor in cancer cell invasion . This naming similarity raises interesting research questions about potential functional relationships. Researchers investigating possible connections could employ several approaches. First, co-localization studies using CPR2/TBRG4 antibody alongside markers for actin filaments and known actin-bundling factors could reveal spatial relationships. Second, biochemical fractionation followed by immunoblotting could determine whether CPR2/TBRG4 associates with cytoskeletal components. Third, proximity labeling techniques like BioID or APEX fusion proteins could identify whether CPR2/TBRG4 exists in the vicinity of actin-regulatory proteins in living cells. Fourth, functional studies comparing phenotypes between CPR2/TBRG4 and CRP2 knockdowns might reveal shared or distinct cellular processes affected by these proteins. Fifth, proteomic approaches using co-immunoprecipitation with CPR2/TBRG4 antibody followed by mass spectrometry could identify direct interacting partners related to cytoskeletal regulation. Finally, researchers should investigate whether the cell cycle regulatory functions attributed to CPR2/TBRG4 involve cytoskeletal reorganization, which often accompanies cell division and could represent a functional intersection with actin-bundling processes.

How can proteomics approaches enhance understanding of CPR2/TBRG4 function in cellular pathways?

Proteomics approaches offer powerful strategies for elucidating CPR2/TBRG4's functional network. First, immunoprecipitation using validated CPR2/TBRG4 antibody followed by mass spectrometry (IP-MS) can identify direct interaction partners, providing insights into the protein complexes where CPR2/TBRG4 functions. Second, proximity labeling methods like BioID or APEX2 fused to CPR2/TBRG4 can map its proximal interactome, capturing both stable and transient interactions in living cells. Third, quantitative proteomics comparing wild-type cells with CPR2/TBRG4 knockdown or knockout models can reveal downstream effectors and pathways influenced by this protein. Fourth, phosphoproteomics analysis could determine whether CPR2/TBRG4 influences cellular signaling networks, particularly those related to cell cycle regulation. Fifth, spatial proteomics approaches like hyperplexed immunofluorescence or imaging mass cytometry using CPR2/TBRG4 antibody alongside other markers can map its distribution relative to functional cellular compartments. Finally, researchers should consider temporal proteomics to track CPR2/TBRG4 interactions throughout cell cycle progression, which would be particularly relevant given its putative role in cell cycle regulation .

What are the considerations for developing monoclonal antibodies against CPR2/TBRG4?

While the current available CPR2/TBRG4 antibody is a rabbit polyclonal , researchers might consider developing monoclonal antibodies for certain applications. This process involves several important considerations. First, epitope selection is crucial; researchers should analyze the protein sequence to identify regions with high antigenicity and low sequence similarity to other proteins, potentially focusing on the leucine zipper domains that characterize this protein . Second, immunogen design must be optimized; options include recombinant protein fragments, synthetic peptides corresponding to unique regions, or full-length protein expressed in eukaryotic systems to preserve native folding. Third, screening strategies should be rigorous; initial ELISA screening should be followed by application-specific validation in Western blot, immunoprecipitation, and immunofluorescence using cells known to express the target (e.g., HepG2, HeLa) . Fourth, isotype selection impacts applications; IgG1 is often preferred for most applications, while IgG2a may offer advantages for certain effector functions. Fifth, epitope mapping should be performed to precisely define binding sites and predict potential cross-reactivity. Finally, researchers should compare new monoclonal antibodies with existing polyclonal reagents across multiple applications to determine relative advantages in specificity, lot-to-lot consistency, and application performance.

How can high-throughput techniques be applied to study CPR2/TBRG4 function across different cellular contexts?

High-throughput approaches can significantly advance understanding of CPR2/TBRG4 function across diverse cellular systems. First, CRISPR-Cas9 screens targeting CPR2/TBRG4 across multiple cell types could reveal context-dependent phenotypes and synthetic lethal interactions, providing insights into cell type-specific functions. Second, single-cell RNA-seq comparing wild-type and CPR2/TBRG4-depleted populations could identify cell state transitions that depend on this protein, particularly relevant given its putative role in cell cycle regulation . Third, automated high-content imaging using CPR2/TBRG4 antibody for immunofluorescence across tissue microarrays or cell line panels could map expression patterns and subcellular localization across hundreds of samples simultaneously. Fourth, multiplexed CRISPR perturbation with transcriptional readouts (Perturb-seq) could reveal gene regulatory networks influenced by CPR2/TBRG4. Fifth, large-scale affinity purification mass spectrometry (AP-MS) screens could identify differential protein interaction networks across cell types or conditions. Finally, researchers should consider integrating multi-omics data (transcriptomics, proteomics, metabolomics) from CPR2/TBRG4 perturbation experiments to construct comprehensive functional networks that might reveal unexpected cellular roles beyond the currently known associations with cell cycle regulation .